ATE442362T1 - Pyridylcyanoguanidin verbindungen - Google Patents

Pyridylcyanoguanidin verbindungen

Info

Publication number: ATE442362T1
Authority: AT; Austria
Prior art keywords: halogen; alkylcarbonyl; aminoalkyl; formyl; alkoxycarbonyl
Prior art date: 2001-05-24

Application number

AT02771630T

Other languages

English (en)

Inventor

Fredrik Bjirkling

Original Assignee

Leo Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-24

Filing date

2002-05-24

Publication date

2009-09-15

2002-05-24 Application filed by Leo Pharma As filed Critical Leo Pharma As

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE442362T1 publication Critical patent/ATE442362T1/de

Links

CPFPCHSTLBKFPH-UHFFFAOYSA-N 1-cyano-1-pyridin-2-ylguanidine Chemical class NC(=N)N(C#N)C1=CC=CC=N1 CPFPCHSTLBKFPH-UHFFFAOYSA-N 0.000 title 1
-1 nitro, carboxy Chemical group 0.000 abstract 6
229910052736 halogen Inorganic materials 0.000 abstract 5
125000003545 alkoxy group Chemical group 0.000 abstract 4
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
125000004448 alkyl carbonyl group Chemical group 0.000 abstract 4
125000004103 aminoalkyl group Chemical group 0.000 abstract 4
125000004093 cyano group Chemical group *C#N 0.000 abstract 4
125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 4
125000005843 halogen group Chemical group 0.000 abstract 4
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
239000004215 Carbon black (E152) Substances 0.000 abstract 3
229930195733 hydrocarbon Natural products 0.000 abstract 3
229920006395 saturated elastomer Polymers 0.000 abstract 3
125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 2
125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
150000001204 N-oxides Chemical class 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical group 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
150000002430 hydrocarbons Chemical class 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
150000002431 hydrogen Chemical group 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
125000006413 ring segment Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Oncology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT02771630T 2001-05-24 2002-05-24 Pyridylcyanoguanidin verbindungen ATE442362T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29292701P	2001-05-24	2001-05-24
US29292801P	2001-05-24	2001-05-24
PCT/DK2002/000353 WO2002094813A1 (en)	2001-05-24	2002-05-24	Novel pyridyl cyanoguanidine compounds

Publications (1)

Publication Number	Publication Date
ATE442362T1 true ATE442362T1 (de)	2009-09-15

Family

ID=26967641

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02771630T ATE442362T1 (de)	2001-05-24	2002-05-24	Pyridylcyanoguanidin verbindungen

Country Status (17)

Country	Link
US (2)	US7304066B2 (de)
EP (1)	EP1397355B1 (de)
JP (1)	JP4429607B2 (de)
KR (1)	KR20030097897A (de)
CN (1)	CN1247570C (de)
AT (1)	ATE442362T1 (de)
BR (1)	BR0209930A (de)
CA (1)	CA2447021C (de)
CZ (1)	CZ20033190A3 (de)
DE (1)	DE60233656D1 (de)
ES (1)	ES2328799T3 (de)
HU (1)	HUP0400021A3 (de)
IL (1)	IL158574A0 (de)
MX (1)	MXPA03010669A (de)
PL (1)	PL366459A1 (de)
RU (1)	RU2292344C2 (de)
WO (1)	WO2002094813A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004041285A1 (en)	2002-10-31	2004-05-21	Amgen Inc.	Antiinflammation agents
CA2554809C (en) *	2004-02-05	2014-04-29	Probiodrug Ag	Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
AR050253A1 (es)	2004-06-24	2006-10-11	Smithkline Beecham Corp	Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
PE20060748A1 (es)	2004-09-21	2006-10-01	Smithkline Beecham Corp	Derivados de indolcarboxamida como inhibidores de quinasa ikk2
ES2572777T3 (es) *	2004-12-22	2016-06-02	Leo Pharma A/S	Compuestos novedosos de cianoguanidina
AR055343A1 (es)	2005-06-30	2007-08-22	Smithkline Beecham Corp	Derivados de indolcarboxamida inhibidores de quinasas ikk2
US8063071B2 (en)	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
RU2011111728A (ru)	2008-08-29	2012-10-10	Топотаргет А/С (Dk)	Новые производные мочевины и тиомочевины
CA2751495C (en) *	2009-02-06	2013-08-20	Tianjin Hemay Bio-Tech Co., Ltd.	Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof
WO2010102968A1 (en)	2009-03-10	2010-09-16	Glaxo Group Limited	Indole derivatives as ikk2 inhibitors
CA2768338A1 (en)	2009-07-17	2011-01-20	Topotarget A/S	Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
CN102740850B (zh) *	2010-02-04	2014-04-02	天津和美生物技术有限公司	吡啶基氰基胍衍生物
WO2011095027A1 (zh) *	2010-02-04	2011-08-11	天津和美生物技术有限公司	吡啶基氰基胍衍生物
US8912184B1 (en)	2010-03-01	2014-12-16	Alzheimer's Institute Of America, Inc.	Therapeutic and diagnostic methods
WO2011121055A1 (en)	2010-03-31	2011-10-06	Topotarget A/S	Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
AR082886A1 (es) *	2010-09-03	2013-01-16	Forma Therapeutics Inc	Compuestos y composiciones farmaceuticas que los contienen
JP2013540781A (ja)	2010-10-26	2013-11-07	ティエンジンホーメイバイオ−テックカンパニー，リミテッド	Ｎ−（６−（４−クロロフェノキシ）ヘキシル）−ｎ’−シアノ−ｎ’’−（４−ピリジル）グアニジンの結晶多形とその製造及び使用
SI2649048T1 (sl) *	2010-12-09	2016-10-28	Radikal Therapeutics Inc.	Večfunkcionalni nitroksid derivati in njih uporaba
SG10201608579UA (en) *	2012-04-13	2016-12-29	Epizyme Inc	Combination therapy for treating cancer
KR101656663B1 (ko)	2015-07-27	2016-09-13	충남대학교산학협력단	암 예방 및 치료용 조성물
PT3837256T (pt)	2018-08-17	2023-05-23	Novartis Ag	Compostos e composições de ureia como inibidores de smarca2/brm-atpase
CN110734405A (zh) *	2019-11-11	2020-01-31	华东数字医学工程研究院	一种n-(6-氨己基)-n’-甲基-2,2’-联咪唑的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5696140A (en) *	1992-09-15	1997-12-09	Leo Pharmaceutical Products Ltd.	N-cyano-N'-pyridylguanidines as serotonin antagonists
GB9219472D0 (en) *	1992-09-15	1992-10-28	Leo Pharm Prod Ltd	Chemical compounds
GB9711124D0 (en) *	1997-05-29	1997-07-23	Leo Pharm Prod Ltd	Novel cyanoguanidines
GB9711122D0 (en)	1997-05-29	1997-07-23	Leo Pharm Prod Ltd	Novel cyanoguanidines
GB9711119D0 (en)	1997-05-29	1997-07-23	Leo Pharm Prod Ltd	Novel cyanoguanidines
GB9711125D0 (en)	1997-05-29	1997-07-23	Leo Pharm Prod Ltd	Novel cyanoguanidines
GB9711123D0 (en)	1997-05-29	1997-07-23	Leo Pharm Prod Ltd	Novel cyanoguanidines
US7129043B1 (en) *	1998-10-22	2006-10-31	Duke University	Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
WO2000061561A1 (en)	1999-04-09	2000-10-19	Shionogi Bioresearch Corp.	Cyanoguanidine compounds
WO2000061559A1 (en)	1999-04-09	2000-10-19	Shionogi Bioresearch Corp.	N-substituted cyanoguanidine compounds
US6645968B2 (en)	1999-08-03	2003-11-11	Abbott Laboratories	Potassium channel openers
WO2001009096A2 (en)	1999-08-03	2001-02-08	Abbott Laboratories	Potassium channel openers

2002
- 2002-05-24 AT AT02771630T patent/ATE442362T1/de not_active IP Right Cessation
- 2002-05-24 BR BR0209930-6A patent/BR0209930A/pt not_active IP Right Cessation
- 2002-05-24 RU RU2003137007/04A patent/RU2292344C2/ru active
- 2002-05-24 WO PCT/DK2002/000353 patent/WO2002094813A1/en not_active Ceased
- 2002-05-24 JP JP2002591486A patent/JP4429607B2/ja not_active Expired - Fee Related
- 2002-05-24 KR KR10-2003-7015244A patent/KR20030097897A/ko not_active Ceased
- 2002-05-24 CZ CZ20033190A patent/CZ20033190A3/cs unknown
- 2002-05-24 ES ES02771630T patent/ES2328799T3/es not_active Expired - Lifetime
- 2002-05-24 CN CNB028101022A patent/CN1247570C/zh not_active Expired - Lifetime
- 2002-05-24 PL PL02366459A patent/PL366459A1/xx not_active Application Discontinuation
- 2002-05-24 HU HU0400021A patent/HUP0400021A3/hu unknown
- 2002-05-24 IL IL15857402A patent/IL158574A0/xx unknown
- 2002-05-24 CA CA2447021A patent/CA2447021C/en not_active Expired - Lifetime
- 2002-05-24 US US10/476,856 patent/US7304066B2/en not_active Expired - Lifetime
- 2002-05-24 DE DE60233656T patent/DE60233656D1/de not_active Expired - Lifetime
- 2002-05-24 EP EP02771630A patent/EP1397355B1/de not_active Expired - Lifetime
- 2002-05-24 MX MXPA03010669A patent/MXPA03010669A/es not_active Application Discontinuation
2007
- 2007-11-30 US US11/998,575 patent/US7807682B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1397355B1 (de)	2009-09-09
US7304066B2 (en)	2007-12-04
BR0209930A (pt)	2004-03-30
HK1066216A1 (en)	2005-03-18
WO2002094813A1 (en)	2002-11-28
MXPA03010669A (es)	2004-07-01
IL158574A0 (en)	2004-05-12
CA2447021A1 (en)	2002-11-28
US7807682B2 (en)	2010-10-05
PL366459A1 (en)	2005-02-07
RU2292344C2 (ru)	2007-01-27
HUP0400021A2 (hu)	2004-04-28
DE60233656D1 (de)	2009-10-22
JP4429607B2 (ja)	2010-03-10
RU2003137007A (ru)	2005-04-20
EP1397355A1 (de)	2004-03-17
ES2328799T3 (es)	2009-11-18
CN1509283A (zh)	2004-06-30
CN1247570C (zh)	2006-03-29
JP2005508859A (ja)	2005-04-07
US20040220408A1 (en)	2004-11-04
US20080090842A1 (en)	2008-04-17
KR20030097897A (ko)	2003-12-31
CA2447021C (en)	2010-08-10
HUP0400021A3 (en)	2008-03-28
CZ20033190A3 (cs)	2004-06-16

Legal Events

Date	Code	Title	Description
2010-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60233656D1 (de)	2009-10-22	Pyridylcyanoguanidin verbindungen
UA84712C2 (en)	2008-11-25	N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
ATE302775T1 (de)	2005-09-15	Carbolinderivate
MY135841A (en)	2008-07-31	Novel benzodioxoles
DK1697371T3 (da)	2007-09-17	Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
MY138737A (en)	2009-07-31	N3-substituted imidazopyridine c-kit inhibitors
MXPA05009359A (es)	2005-11-04	Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
BG108269A (en)	2004-12-30	Pyrazolopyrimidines as therapeutic agents
PL377285A1 (pl)	2006-01-23	Podstawione pochodne pirolo-pirazolowe jako inhibitory kinazy
IL189694A0 (en)	2008-06-05	Biphenyl derivatives and their use in treating hepatitis c
IL164511A0 (en)	2005-12-18	Heterocyclic compounds
BG108268A (en)	2005-04-30	Pyrazolopyrimidines as therapeutic agents
NO20091409L (no)	2009-04-07	Pyridin-3-yl-derivater som immunmodulerende midler
MY144622A (en)	2011-10-14	Agents for preventing and treating disorders involving modulation of the ryr receptors
MX2007000505A (es)	2007-06-25	Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
ATE346067T1 (de)	2006-12-15	Carbolinderivate
AU2002213421A1 (en)	2002-04-15	Condensed pyridoindole derivatives
MY139612A (en)	2009-10-30	Benzoxazine derivatives as 5-th6 modulators and uses thereof
NO20082214L (no)	2008-07-31	1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
ATE297904T1 (de)	2005-07-15	Halo-alkoxycarbonylverbindungen
TW200508199A (en)	2005-03-01	Novel compound
MXPA02012470A (es)	2004-01-26	Inhibidores de fosfodiesterasa especificos para gmp ciclico.
MXPA03002909A (es)	2003-09-10	Compuestos quimicos.
ATE135206T1 (de)	1996-03-15	Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung
MXPA03003971A (es)	2004-02-12	Derivados de indol como inhibidores de pde5.